Already a leader in the treatment of prostate and breast cancer,Pfizer,the world's largest pharmaceutical company,has further enlarged its oncology portfolio by completing its acquisition of Array BioPharma,Inc.,the company announced on 30 July 2019.This will advance breakthrough science for the discovery,development and commercialisation of targeted small molecule medicines to treat cancer and other diseases of high unmet need,Pfizer said.*
Array's portfolio included the approved combined use of BRAFTOVI (R) and MEKTOVI (R) for the treatment of two forms of unresectable or metastatic melanoma skin cancer,with significant potential for long-term growth with expansion into additional areas of unmet need.The combination is also being investigated as a potential first-in-class combination for the treatment of BRAF-mutant metastatic colorectal cancer (mCRC),based on interim results the company feels are compelling from the pivotal Phase 3 BEACON trial,according to Pfizer.They believe this application has industry-leading potential.*
Pfizer says it will maintain Array's operations in Cambridge,Massachusetts;Morrisville,North Carolina;and Boulder,Colorado.Array is now a wholly-owned subsidiary of the New York-based pharma titan.The all-cash deal had a value of around 11.4 billion dollars.*
Pfizer Inc (PFE)
No comments:
Post a Comment